Skip to main content Back to Top
Advertisement

11/4/2019

Sufentanil Injection

Products Affected - Description

    • Sufenta solution for injection, Akorn, 50 mcg/mL, 5 mL ampule, 10 count, NDC 17478-0050-05
    • Sufentanil solution for injection, Pfizer, 50 mcg/mL, 1 mL vial, 10 count, NDC 00409-3382-21
    • Sufentanil solution for injection, Pfizer, 50 mcg/mL, 2 mL vial, 10 count, NDC 00409-3382-22
    • Sufentanil solution for injection, Pfizer, 50 mcg/mL, 5 mL vial, 10 count, NDC 00409-3382-25

Reason for the Shortage

    • Akorn had Sufenta injection on shortage due to increased demand for the product.
    • Hikma stopped marketing sufentanil injection in October 2018.
    • Pfizer has sufentanil injection on shortage due to manufacturing delays.

Available Products

    • Sufenta solution for injection, Akorn, 50 mcg/mL, 1 mL ampule, 10 count, NDC 17478-0050-01
    • Sufenta solution for injection, Akorn, 50 mcg/mL, 2 mL ampule, 10 count, NDC 17478-0050-02

Estimated Resupply Dates

    • Akorn has Sufenta 0.5 mg/mL 5 mL ampules on allocation.
    • Pfizer has sufentanil 0.5 mg/mL 1 mL, 2 mL, and 5 mL vials on back order and the company estimates a release date of November 2019.

Implications for Patient Care

    • ASHP has an FAQ on the injectable opioid shortage at https://www.ashp.org/Drug-Shortages/Shortage-Resources/Injectable-Opioid-Shortages-FAQ. This discusses multiple issues including inventory and pharmacy operational strategies.

Updated

Updated November 4, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created January 12, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins